Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients

Journal of Neuroimmunology

Volumn 230, Issue 1-2, 2011, Pages 153-159

  Oliver Martos, B ^a   Orpez T ^a   Pinto Medel, M J ^a   Mayorga, C ^a   Garcia Leon J A ^a   Maldonado Sanchez, R ^a   Suardiaz M ^a   Guerrero, M ^a   Luque, G ^a   Leyva, L ^a   Fernandez O ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Gene expression; Interferon beta receptor; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; ALPHA INTERFERON RECEPTOR 2; BETA INTERFERON; INTERFERON REGULATORY FACTOR 9; JANUS KINASE; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-BETA; MALE; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTOR, INTERFERON ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 78650989310     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.10.033     Document Type: Article

References (45)

1. Anderton S.M., Liblau R.S. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr. Opin. Neurol. 2008, 21(3):248-254. Jun.
2. Benjamin Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57:289-300. (Abstract).
3. Brettschneider J., Jaskowski T.D., Tumani H., Abdul S., Husebye D., Seraj H., Hill H.R., Fire E., Spector L., Yarden J., Dotan N., Rose J.W. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J. Neuroimmunol. 2009, 217:95-101.
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
5. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julia E., Fernandez M., Nonell L., Camina-Tato M., Deisenhammer F., Caballero E., Tortola M.T., Prinz M., Montalban X., Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
6. Croze E., Russell-Harde D., Wagner T.C., Pu H., Pfeffer L.M., Perez H.D. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J. Biol. Chem. 1996, 271:33165-33168.
7. Dupont S.A., Goelz S., Goyal J., Green M. Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J. Interferon Cytokine Res. 2002, 22:491-501.
8. Feng X., Yau D., Holbrook C., Reder A.T. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J. Interferon Cytokine Res. 2002, 22:311-319.
9. Fenner J.E., Starr R., Cornish A.L., Zhang J.G., Metcalf D., Schreiber R.D., Sheehan K., Hilton D.J., Alexander W.S., Hertzog P.J. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 2006, 7:33-39.
10. Friese M.A., Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005, 128:1747-1763.
11. Frisullo G., Angelucci F., Caggiula M., Nociti V., Iorio R., Patanella A.K., Sancricca C., Mirabella M., Tonali P.A., Batocchi A.P. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 2006, 84:1027-1036.
12. Gilli F., Valentino P., Caldano M., Granieri L., Capobianco M., Malucchi S., Sala A., Marnetto F., Bertolotto A. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 2008, 71:1940-1947.
13. Hesse D., Sellebjerg F., Sorensen P.S. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009, 73(5):372-377. Aug 4.
14. Hesse D., Krakauer M., Lund H., Søndergaard H.B., Limborg S.J., Soelberg Sørensen P., Sellebjerg F. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur. J. Neurol. 2010, 15. Jun.
15. Ito K., Tanaka H., Ito T., Sultana T.A., Kyo T., Imanaka F., Ohmoto Y., Kimura A. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur. J. Haematol. 2004, 73:191-205.
16. Kauffman M.A., Yankilevich P., Barrero P., Bello R., Marangunich L., Vidal A., Criscuolo M., Diez R.A., Sterin Prync A. Whole genome analysis of the action of interferon-beta. Int. J. Clin. Pharmacol. Ther. 2009, 47:328-357.
17. Kawade Y., Finter N., Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 2003, 278:127-144.
18. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
19. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
20. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
21. Lutfalla G., Gardiner K., Proudhon D., Vielh E., Uze G. The structure of the human interferon alpha/beta receptor gene. J. Biol. Chem. 1992, 267:2802-2809.
22. Malucchi S., Gilli F., Caldano M., Marnetto F., Valentino P., Granieri L., Sala A., Capobianco M., Bertolotto A. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008, 70:1119-1127.
23. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
24. Oliver B., Mayorga C., Fernandez V., Leyva L., Leon A., Luque G., Lopez J.C., Tamayo J.A., Pinto-Medel M.J., de Ramon E., Blanco E., Alonso A., Fernandez O. Interferon receptor expression in multiple sclerosis patients. J. Neuroimmunol. 2007, 183:225-231.
25. Oliver B., Orpez T., Mayorga C., Pinto-Medel M.J., Leyva L., Lopez-Gomez C., Marin C., Luque G., Ortega-Pinazo J., Fernandez O. Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection. J. Immunol. Meth. 2009, 351:41-45.
26. Pachner A.R., Dail D., Pak E., Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 2005, 166:180-188.
27. Paun A., Pitha P.M. The IRF family, revisited. Biochimie 2007, 89:744-753.
28. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., Lucas M., Basso A.S., Khoury S.J., Lucchinetti C.F., Cohen I.R., Weiner H.L. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl Acad. Sci. USA 2008, 105:18889-18894.
29. Rani M.R., Croze E., Wei T., Shrock J., Josyula A., Kalvakolanu D.V., Ransohoff R.M. STAT-phosphorylation-independent induction of interferon regulatory factor-9 by interferon-beta. J. Interferon Cytokine Res. 2010, 30:163-170.
30. Reder A.T., Velichko S., Yamaguchi K.D., Hamamcioglu K., Ku K., Beekman J., Wagner T.C., Perez H.D., Salamon H., Croze E. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J. Interferon Cytokine Res. 2008, 28:317-331.
31. Schindler C., Strehlow I. Cytokines and STAT signaling. Adv. Pharmacol. 2000, 47:113-174.
32. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., Sorensen P.S. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
33. Serana F., Sottini A., Ghidini C., Zanotti C., Capra R., Cordioli C., Caimi L., Imberti L. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J. Neuroimmunol. 2008, 197:54-62.
34. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 2005, 5:593-605.
35. Singh M.K., Scott T.F., LaFramboise W.A., Hu F.Z., Post J.C., Ehrlich G.D. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J. Neurol. Sci. 2007, 258:52-59.
36. Sominanda A., Hillert J., Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J. Neurol. Neurosurg. Psychiatry 2008, 79:57-62.
37. Sonobe Y., Jin S., Wang J., Kawanokuchi J., Takeuchi H., Mizuno T., Suzumura A. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Tohoku J. Exp. Med. 2007, 213:329-339.
38. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., Stenager E., Koch-Henriksen N. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003, 362:1184-1191.
39. Sorensen P.S., Tscherning T., Mathiesen H.K., Langkilde A.R., Ross C., Ravnborg M., Bendtzen K. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006, 67:1681-1683.
40. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003, 126:1419-1429.
41. Velazquez L., Fellous M., Stark G.R., Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992, 70:313-322.
42. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 2003, 171:2694-2702.
43. Weinstock-Guttman B., Bhasi K., Badgett D., Tamano-Blanco M., Minhas M., Feichter J., Patrick K., Munschauer F., Bakshi R., Ramanathan M. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J. Neuroimmunol. 2008, 205:113-125.
44. Wu W.Z., Sun H.C., Gao Y.Q., Li Y., Wang L., Zhou K., Liu K.D., Iliakis G., Tang Z.Y. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 2004, 67:428-440.
45. Yamada S., Shiono S., Joo A., Yoshimura A. Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett. 2003, 534:190-196.